[go: up one dir, main page]

ECSP11011435A - Combinación antitumoral que comprende cabazitaxel y capecitabina - Google Patents

Combinación antitumoral que comprende cabazitaxel y capecitabina

Info

Publication number
ECSP11011435A
ECSP11011435A EC2011011435A ECSP11011435A ECSP11011435A EC SP11011435 A ECSP11011435 A EC SP11011435A EC 2011011435 A EC2011011435 A EC 2011011435A EC SP11011435 A ECSP11011435 A EC SP11011435A EC SP11011435 A ECSP11011435 A EC SP11011435A
Authority
EC
Ecuador
Prior art keywords
capecitabina
combination including
cabazitaxel
antitumoral combination
antitumoral
Prior art date
Application number
EC2011011435A
Other languages
English (en)
Inventor
Emmanuelle Magherini
Original Assignee
Sanofi Adventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Adventis filed Critical Sanofi Adventis
Publication of ECSP11011435A publication Critical patent/ECSP11011435A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La invención se refiere a una combinación farmacéutica antitumoral que comprende cabazitaxel y capecitabina, pudiendo estar estos dos agentes antitumorales en forma de base, en forma de una sal de un ácido farmacéuticamente aceptable o en forma de un hidrato o de un solvato, destinada a tratar el cáncer de mama metastásico en los pacientes que progresan después de un tratamiento anterior con antraciclinas y taxanos.
EC2011011435A 2009-05-06 2011-11-01 Combinación antitumoral que comprende cabazitaxel y capecitabina ECSP11011435A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0902189A FR2945211A1 (fr) 2009-05-06 2009-05-06 Combinaison antitumorale comprenant la cabazitaxel et la capecitabine
FR0902264A FR2945212B1 (fr) 2009-05-06 2009-05-11 Combinaison antitumorale comprenant le cabazitaxel et la capecitabine

Publications (1)

Publication Number Publication Date
ECSP11011435A true ECSP11011435A (es) 2011-12-30

Family

ID=41168737

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2011011435A ECSP11011435A (es) 2009-05-06 2011-11-01 Combinación antitumoral que comprende cabazitaxel y capecitabina

Country Status (25)

Country Link
US (1) US20120115806A1 (es)
EP (1) EP2427187A1 (es)
JP (1) JP2012526089A (es)
KR (1) KR20120008069A (es)
CN (1) CN102458392A (es)
AU (1) AU2010244253A1 (es)
BR (1) BRPI1011827A2 (es)
CA (1) CA2761079A1 (es)
CL (1) CL2011002774A1 (es)
CO (1) CO6390103A2 (es)
CR (1) CR20110586A (es)
DO (1) DOP2011000336A (es)
EA (1) EA201171360A1 (es)
EC (1) ECSP11011435A (es)
FR (2) FR2945211A1 (es)
IL (1) IL216063A0 (es)
MA (1) MA33343B1 (es)
MX (1) MX2011011765A (es)
NI (1) NI201100192A (es)
NZ (1) NZ596226A (es)
PE (1) PE20120348A1 (es)
SG (1) SG175894A1 (es)
TN (1) TN2011000542A1 (es)
WO (1) WO2010128258A1 (es)
ZA (1) ZA201108109B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA024186B1 (ru) 2009-10-29 2016-08-31 Авентис Фарма С.А. Применение кабазитаксела в комбинации с преднизоном или преднизолоном для лечения рака простаты
CN102068407B (zh) * 2010-12-27 2011-11-23 江苏奥赛康药业股份有限公司 一种cabazitaxel注射液及其制备方法
ES2745506T3 (es) 2011-02-25 2020-03-02 Sanofi Mature Ip Combinación antitumoral que comprende cabazitaxel y cisplatino
EP2620148A1 (en) 2012-01-27 2013-07-31 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
EP2491925A1 (en) 2011-02-25 2012-08-29 Aventis Pharma S.A. Antitumoral combination comprising cabazitaxel and cisplatin
CN106573077B (zh) 2014-06-30 2019-07-30 塔弗达治疗有限公司 靶向缀合物及其颗粒和制剂
CN108473538B (zh) 2015-10-28 2022-01-28 塔弗达治疗有限公司 Sstr靶向缀合物及其颗粒和制剂

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU671491B2 (en) 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
FR2859996B1 (fr) * 2003-09-19 2006-02-03 Aventis Pharma Sa Solvat acetonique du dimethoxy docetaxel et son procede de preparation

Also Published As

Publication number Publication date
FR2945211A1 (fr) 2010-11-12
FR2945212B1 (fr) 2011-07-01
CL2011002774A1 (es) 2012-04-20
EP2427187A1 (fr) 2012-03-14
CR20110586A (es) 2011-12-13
IL216063A0 (en) 2012-01-31
FR2945212A1 (fr) 2010-11-12
PE20120348A1 (es) 2012-04-24
MA33343B1 (fr) 2012-06-01
KR20120008069A (ko) 2012-01-25
ZA201108109B (en) 2013-01-30
CN102458392A (zh) 2012-05-16
TN2011000542A1 (fr) 2013-05-24
EA201171360A1 (ru) 2012-05-30
CO6390103A2 (es) 2012-02-29
SG175894A1 (en) 2011-12-29
NZ596226A (en) 2014-01-31
US20120115806A1 (en) 2012-05-10
WO2010128258A1 (fr) 2010-11-11
CA2761079A1 (fr) 2010-11-11
BRPI1011827A2 (pt) 2016-03-22
JP2012526089A (ja) 2012-10-25
AU2010244253A1 (en) 2011-11-24
NI201100192A (es) 2012-01-23
MX2011011765A (es) 2012-06-01
DOP2011000336A (es) 2011-12-15

Similar Documents

Publication Publication Date Title
CR20110586A (es) Combinación antitumoral que comprende cabazitaxel y capecitabina
MX2013010340A (es) Combinacion de terapias inmunomoduladoras local y sistemica para tratamiento mejorado del cancer.
NZ593343A (en) Combination cancer treatment conprising Abraxane and an inflamatory inhibitor
MX394252B (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf
AR124500A2 (es) Aumento de la biodisponibilidad de droga en terapia naltrexona
RU2016112608A (ru) Лечение рака комбинацией плинабулина и таксана
NZ703047A (en) Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2016025635A3 (en) Combination therapy for treating cancer
NI201200030A (es) Tratamiento anticancerígeno con una combinación de taxanos y 13-dexosiantraciclinas.
AR029084A1 (es) Composiciones y metodos para el tratamiento del cancer
MX2013000779A (es) Metodos para tratar cancer de mama utilizando 4-yodo-3-nitrobenzamida en combinacion con agentes antitumorales.
UY32987A (es) Nuevo uso antitumoral de cabazitaxel
WO2016043874A3 (en) Combination therapy for treating cancer
JP2015502926A5 (es)
AR067420A1 (es) Combinaciones antitumorales que contienen un agente inhibidor del factor de crecimiento vascular endotelial (vegf) y del irinotecan
ECSP14013195A (es) Catéter, en particular catéter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la próstata.
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
BRPI0810384B8 (pt) terapia enzimática anticâncer
AR086422A1 (es) Metodo para el tratamiento de tumores solidos avanzados, volasertib
MX2018013873A (es) Irinotecan nanoliposomico para usarse en el tratamiento del cancer de pulmon de celulas pequeñas.
CO2022015891A2 (es) Administración conjunta de mirdametinib y lifirafenib para uso en el tratamiento de cánceres
CO6390102A2 (es) Combinacion anitumoral que comprende ave8062 y sorafenib
ZA200807323B (en) Use of CK2 inhibitor for the treatment and chemosensibilization of refractory tumors to anticancer drugs
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
EA201200190A1 (ru) Фулвестрант в дозе 500 мг для лечения распространенного рака молочной железы